Simplex3 40MG
$185.00
The world’s first quad-receptor research peptide – maximum volume format. GIP + GLP-1 + Glucagon + Ghrelin — a retatrutide-class backbone with proprietary ghrelin prokinetic mechanism via PEG4 spacer. C18 diacid lipidation at Lys17 for once-weekly half-life targeting. 99% purity HPLC verified. LCMS mass confirmed. Batch-specific COA with every order. Patent pending. For laboratory research use only.
Simplex3 (40mg) – Quad-Receptor Research Overview
Simplex3 is a research-grade synthetic peptide representing the first quad-receptor agonist design in the GLP-class category. The 40mg vial is the maximum volume format, the lowest cost per milligram in the Simplex3 catalog and the appropriate choice for extended research programs, multi-dose experimental designs, or long-duration pharmacokinetic studies. LOT 006001 / BATCH 001.
Where retatrutide pioneered the triple GIP/GLP-1/Glucagon receptor stack, Simplex3 appends a fourth mechanism, partial ghrelin receptor (GHS-R1a) agonism, targeting the tolerability limitation that has constrained every GLP-class compound before it.
The Four-Receptor Stack
GLP-1 receptor activity (31%):Â glucose-dependent insulin secretion, satiety signaling, glucagon suppression.
GIP receptor activity (24%):Â enhanced glucose-dependent insulin response, energy partitioning, reduced lipid storage at adipose tissue.
Glucagon receptor activity (22%):Â increased resting energy expenditure, hepatic glucose modulation, enhanced fat oxidation.
Ghrelin receptor partial agonism (15%) – the novel fourth mechanism: GHS-R1a activation is the only known prokinetic mechanism that directly counteracts GLP-1-induced delayed gastric emptying. Where every GLP-class compound before Simplex3 accepts nausea and gastroparesis as a trade-off for efficacy, the ghrelin prokinetic mechanism addresses the root cause, accelerating gastric motility through the opposite pathway to GLP-1. Real-world observational data from SIMPLEX-G2 (same prokinetic mechanism at 7.5mg) documents appetite suppression with no GLP-class GI symptoms prior to formal Simplex3 trials.
Structural Features
Proprietary ghrelin fragment (Gly-Ser-Dap(N-octanoyl)-Phe-NHâ‚‚) appended to a retatrutide-derived GIP/GLP-1/Glucagon backbone via PEG4 spacer. C18 diacid lipidation at Lys17 for albumin binding and once-weekly half-life targeting. Novel composition of matter. Patent pending.
Analytical Verification — LOT 006001 / BATCH 001
- Purity (HPLC): ≥ 99.0% — Pass
- Net weight: 40mg ± 0.3% — Pass
- Mass confirmation (LCMS): match within 0.5 Da — Pass
- Endotoxin: < 5 EU/kg — Pass
- Bioburden: < 10 CFU/vial — Pass
- Amino acid analysis: sequence verified — Pass
- Residual solvents: < ICH limits — Pass
- Water content (KF): < 3.0% w/w — Pass
What Every Vial Ships With
- Batch-specific Certificate of Analysis
- LCMS chromatogram and mass confirmation
- Endotoxin and residual solvent reports
- Reconstitution protocol and handling guide
- Cold-chain compatible packaging
Research Context
No controlled human clinical trial data exists for Simplex3. The ghrelin prokinetic mechanism is supported by peer-reviewed preclinical and clinical research on GHS-R1a agonists and by real-world observational data from SIMPLEX-G2 at 7.5mg. The GIP/GLP-1/Glucagon backbone is derived from published retatrutide structural data (Eli Lilly, LY3437943). Patent pending.
Not approved by the FDA for human or veterinary therapeutic use. Sold for laboratory research purposes only.
For laboratory research use only. Not intended for human or veterinary consumption. Not FDA approved for any indication.
Related products
